Novel oral contraceptive for heavy menstrual bleeding: estradiol valerate and dienogest

  title={Novel oral contraceptive for heavy menstrual bleeding: estradiol valerate and dienogest},
  author={Sally Rafie and Laura M Borgelt and Erin R Koepf and Mary E Temple-Cooper and Katherine Joy Lehman},
  journal={International Journal of Women's Health},
  pages={313 - 321}
Abnormal uterine bleeding (AUB) is associated with significant direct medical costs and impacts both society and the quality of life for individual women. Heavy menstrual bleeding, a subset of AUB, also referred to as menorrhagia, is defined as menstrual blood loss greater than 80 mL or the patient’s perception of excessive blood loss. The newest treatment option available is a novel combination oral contraceptive product containing estradiol valerate (E2V) and dienogest (DNG). As with other… Expand
Combined Oral Contraceptive for Treatment of Women with Uterine Fibroids and Abnormal Uterine Bleeding: A Systematic Review
Assessment of the efficacy of combined oral contraceptives in treating women with uterine leiomyomata and heavy menstrual bleeding as well as their effect over quality of life, tumor size, and hemoglobin concentration found evidence of very scarce and low quality evidence is very uncertain. Expand
Non-steroidal anti-inflammatory drugs for heavy menstrual bleeding.
NSAIDs were more effective than placebo at reducing HMB but less effective than either tranexamic acid, danazol or the levonorgestrel-releasing intrauterine system (LNG IUS), while most studies were underpowered. Expand
An update on new orally administered contraceptives for women
  • A. Nelson
  • Medicine
  • Expert opinion on pharmacotherapy
  • 2015
This article reviews the features of each of the four new oral contraceptives that have been introduced in the United States and/or Europe in the last few years and concludes that cost will continue to be the determining factor in the acceptance of these new products, unless substantial health benefits can be conclusively proven. Expand
Contraception for Women with Hematologic Abnormalities
The most effective methods of long-term reversible contraception (intrauterine devices and the subdermal implant) are usually safe for use in women with hematologic disorders and should be offered as top-tier methods. Expand
A comparison of two different oral contraceptives in patients with severe primary dysmenorrhoea
Estradiol valerate/dienogest, which is a routinely prescribed drug for heavy menstrual bleeding in women who desire oral contraception, is as effective as ethinylestradiol/drospirenone in pain relief. Expand
Effects of estradiol valerate and dienogest on quality of life and sexual function according to age.
The E2V/DNG pill is associated with a significant improvement of GH and VT and with an improvement in FSF with no difference between age groups. Expand
Contraception and Sterilization
Increased efforts should be made to reduce health disparities and allow all women access to the most effective contraceptive methods and to the method they find best suits their lifestyle. Expand
Polycystic ovary syndrome: chemical pharmacotherapy
The authors review the drugs used for PCOS management and discuss new approaches, and an accurate evaluation of patients’ characteristics is performed, identifying the phenotypic target and, subsequently, the best-tailored treatment to manage one or more clinical issues. Expand
Dienogest - The Millennium Molecule!!
Dienogest (DNG) is a fourth-generation progestin, being extensively used in a wide variety of clinical settings in gynecology. In order to write this comprehensive review, a literature search wasExpand
J Gynecol 2017, 2(2): 000140
Introduction: The Global Total Fertility (GTF) rate is projected to decline to 2.4 children per woman by 2030 and 2.2 by 2050. The importance of family planning in promoting maternal and child healthExpand


Progesterone/progestogen releasing intrauterine systems versus either placebo or any other medication for heavy menstrual bleeding.
The primary outcome was reduction in menstrual blood loss but incidence of side effects, changes in quality of life and satisfaction and acceptability measures were also assessed. Expand
Progesterone or progestogen-releasing intrauterine systems for heavy menstrual bleeding.
The effectiveness and acceptability of progesterone or progestogen-releasing intrauterine devices in achieving a reduction in heavy menstrual bleeding is determined and Progestasert has been compared to a number of different medical therapies in one small study. Expand
Normalization of blood loss in women with heavy menstrual bleeding treated with an oral contraceptive containing estradiol valerate/dienogest.
E₂V/DNG is highly effective for the treatment of HMB and is associated with a high rate of treatment success, according to a pooled analysis of data from two identically designed randomized, placebo-controlled, multiple center studies conducted in Europe, Australia and North America. Expand
Effective Treatment of Heavy Menstrual Bleeding With Estradiol Valerate and Dienogest: A Randomized Controlled Trial
Oral E2 valerate and dienogest was highly effective compared with placebo in the treatment of women with heavy menstrual bleeding, prolonged menstrual bleed, or heavy and prolonged menstrual bleeding without organic pathology. Expand
Review of clinical experience with estradiol in combined oral contraceptives.
More recent studies employing endometrial-focused progestins, e.g., DNG, and multiphasic dosing regimens appear to be a promising approach for an E2-based COC that provides efficient ovulation inhibition and acceptable cycle control. Expand
Effective treatment of heavy and/or prolonged menstrual bleeding with an oral contraceptive containing estradiol valerate and dienogest: a randomized, double-blind Phase III trial.
E(2)V/DNG is an effective treatment in women with heavy and/or prolonged menstrual bleeding without organic pathology and a return to 'menstrual normality' during a 90-day efficacy phase. Expand
Estradiol valerate and dienogest: a new approach to oral contraception
Estradiol valerate plus dienogest (E2V/DNG) is now available in a four-phasic regimen that integrates an estrogen stepdown and progestin stepup dosing approach along with a short two-day hormone-free interval. Expand
Nonsteroidal anti-inflammatory drugs for heavy menstrual bleeding.
NSAIDs were more effective than placebo at reducing heavy menstrual bleeding but less effective than either tranexamic acid or danazol, although these results were based on very small studies. Expand
Bleeding pattern and cycle control with an estradiol-based oral contraceptive: a seven-cycle, randomized comparative trial of estradiol valerate/dienogest and ethinyl estradiol/levonorgestrel.
A novel OC composed of E2V/DNG is associated with an acceptable bleeding profile that is comparable to that of an EE-containing OC. Expand
Estradiol valerate/dienogest: a novel combined oral contraceptive.
Estradiol valerate/dienogest is a new contraceptive formulation that offers efficacy, tolerability, and an acceptable safety profile with a potentially better bleeding pattern than levonorgestrel-containing COCs. Expand